---
id: 238
title: Chronic Hepatitis B
category: clinical_syndromes
subcategory: viral
tags: [hepatitis-B, HBV, tenofovir, entecavir, cirrhosis, HBeAg]
difficulty: high
---

## Question

How is chronic hepatitis B managed? Use **"Treat if HBV DNA >2000 + ALT Elevated OR Cirrhosis: Tenofovir or Entecavir Indefinitely"** framework.

## Answer

### **Phases of Chronic HBV:**

**1. Immune Tolerant (HBeAg+):**
- **High HBV DNA** (>10⁷ IU/mL), **normal ALT**
- **Minimal liver inflammation**
- **Do NOT treat** (unless cirrhosis or family history HCC)

**2. Immune Active (HBeAg+):**
- **Elevated HBV DNA** (>2000 IU/mL), **elevated ALT**
- **Active hepatitis** (liver inflammation, fibrosis progression)
- **TREAT**

**3. Inactive Carrier (HBeAg-, Anti-HBe+):**
- **Low/undetectable HBV DNA** (<2000 IU/mL), **normal ALT**
- **HBsAg+** (chronic infection, but inactive)
- **Do NOT treat** (monitor)

**4. HBeAg-Negative Chronic Hepatitis:**
- **HBeAg-**, **elevated HBV DNA** (>2000 IU/mL), **elevated ALT**
- **Active hepatitis** despite HBeAg seroconversion
- **TREAT**

### **Indications for Treatment:**

**Treat if:**
1. **HBV DNA >2000 IU/mL** + **ALT >2× ULN**
2. **Cirrhosis** (regardless of HBV DNA/ALT)
3. **Family history of HCC** (consider treatment even if immune tolerant)
4. **Extrahepatic manifestations** (polyarteritis nodosa, glomerulonephritis)

**Do NOT Treat:**
- **Immune tolerant** (high DNA, normal ALT, no cirrhosis)
- **Inactive carrier** (low DNA, normal ALT)

### **Treatment:**

**First-Line (Nucleos(t)ide Analogues):**

**Preferred:**
- **Tenofovir alafenamide (TAF) 25mg PO daily** (indefinitely)
  - **Lower bone/renal toxicity** than TDF
- **Tenofovir disoproxil fumarate (TDF) 300mg PO daily** (indefinitely)
  - **Monitor bone density, renal function** (Cr, PO₄)
- **Entecavir 0.5mg PO daily** (indefinitely)
  - **1mg daily** if lamivudine-resistant

**Advantages:**
- **High barrier to resistance** (<1% resistance with tenofovir, entecavir)
- **Potent viral suppression**

**Older Agents (NOT Recommended):**
- **Lamivudine, adefovir, telbivudine** - high resistance rates

**Pegylated Interferon-α (Alternative):**
- **PEG-IFN-α 180 mcg SC weekly × 48 weeks** (finite duration)
- **Less commonly used** (side effects, limited efficacy)
- **Advantages:** Finite duration, higher HBsAg seroclearance (vs. nucle os(t)ides)
- **Consider if:** Young, non-cirrhotic, want to avoid lifelong therapy

### **Treatment Goals:**

**Primary:**
- **Undetectable HBV DNA** (<20 IU/mL)
- **ALT normalization**
- **Prevent cirrhosis, HCC**

**Ideal (Rare with Nucle os(t)ides, ~5-10%):**
- **HBsAg seroclearance** ("functional cure")
- **Develop anti-HBs**

**Stopping Treatment:**
- **Generally indefinite** (reactivation common if stopped)
- **Consider stopping** if HBsAg seroclearance (rare)

### **Monitoring:**

**On Treatment:**
- **HBV DNA** q3-6 months (goal: undetectable)
- **ALT** q3-6 months
- **HBsAg quantitative** annually (if considering stopping treatment)
- **Renal function, PO₄** (if on TDF) q6-12 months
- **Bone density** (if on TDF, risk factors for osteoporosis)

**HCC Surveillance:**
- **Ultrasound ± AFP q6 months** (if cirrhosis, high-risk)

### **Special Situations:**

**Pregnancy:**
- **Screen all pregnant women** (HBsAg)
- **If high viral load (>200,000 IU/mL):**
  - **TDF 300mg daily** starting week 28-32 (reduces vertical transmission)
- **Infant:**
  - **HBIG 0.5 mL IM + HBV vaccine** (within 12h of birth)
  - **Complete vaccine series** (reduces transmission from ~90% to <5%)

**HIV Co-Infection:**
- **Treat HBV if HIV treated** (tenofovir + emtricitabine or lamivudine covers both)

**Renal Insufficiency:**
- **Prefer TAF** (less nephrotoxic than TDF)
- **Dose adjust entecavir** (if CrCl <50)

**HBV Reactivation (Immunosuppression):**
- **Risk:** Chemotherapy, rituximab, anti-TNF, corticosteroids, transplant
- **Prophylaxis:**
  - **If HBsAg+:** Entecavir or tenofovir (start before immunosuppression, continue ≥6-12 months after)
  - **If HBsAg-, anti-HBc+** (past infection): Monitor HBV DNA monthly OR give prophylaxis (if high-risk immunosuppression like rituximab)

### **Complications:**

**Cirrhosis:**
- **15-40%** of untreated chronic HBV develop cirrhosis (over 20-30 years)
- **Decompensation risk:** 20% over 5 years

**Hepatocellular Carcinoma (HCC):**
- **Annual incidence 2-5%** (if cirrhosis)
- **Risk persists** even with viral suppression (but reduced)

**Extrahepatic:**
- **Polyarteritis nodosa, glomerulonephritis** (HBV immune complex deposition)

## Key Points

### **Treat if HBV DNA >2000 + ALT Elevated:**
- **OR if cirrhosis** (regardless of DNA/ALT)

### **Tenofovir or Entecavir Indefinitely:**
- **TAF 25mg daily** OR **TDF 300mg daily** OR **entecavir 0.5mg daily**
- **High barrier to resistance**

### **Goal = Undetectable HBV DNA:**
- **Prevent cirrhosis, HCC**
- **HBsAg seroclearance** rare (5-10%)

### **Pregnancy = TDF if High Viral Load:**
- **If HBV DNA >200,000:** TDF 300mg daily (week 28-32)
- **Infant:** HBIG + vaccine within 12h

### **HCC Surveillance:**
- **Ultrasound ± AFP q6 months** (if cirrhosis, high-risk)

### **Clinical Pearls:**
- **Treat if:** HBV DNA >2000 + ALT >2× ULN OR cirrhosis
- **Tenofovir (TAF/TDF) or entecavir** indefinitely (high barrier to resistance)
- **Goal:** Undetectable HBV DNA, prevent cirrhosis/HCC
- **Pregnancy:** TDF if DNA >200,000 (week 28-32), infant HBIG + vaccine
- **HCC surveillance:** Ultrasound q6 months (if cirrhosis)
- **Reactivation risk:** Chemotherapy, rituximab → prophylaxis (entecavir/tenofovir)

## Sources

- [AASLD: Hepatitis B Guidelines 2024]
- [EASL: HBV Management 2024]

## Media

N/A
